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To the Editor,
Immunoglobulin light chains not associated with heavy 
chains free light chains (FLC) are found in serum. A 
growing clinical importance has been assigned to the 
quantification of the κ and λ FLC in serum in the manage­
ment of plasma cell dyscrasias [1, 2].
The FLC may be detected as an isolated band on immu­
nofixation, but this technique is unsuitable for quantifica­
tion if the band is in trace amounts, nor can the FLC be 
quantified by protein electrophoresis unless the band sig­
nificantly alters the electrophoretic profile of plasma pro­
teins. At present, automated immunoassays are the only 
available techniques allowing quantitative determination 
of serum FLC [3].
Unfortunately, the two reagents available for FLC 
assay, Freelite® (The Binding Site Ltd., UK) and N Latex FLC 
(Siemens Healthcare Diagnostics GmbH, Germany), some­
times provide divergent results, especially for the λ FLC 
assay [4]. It has been proposed that the different results, 
unpredictably affecting individual serum samples, are due 
to the different reactivity of reagents against FLC oligomers 
that are known to be present to a variable extent in serum, 
especially when λ FLCs are involved [5]. Only indirect evi­
dence has been provided for this hypothesis to date.
The clinical validity of the results of the two assays 
is considered equivalent but the quantitative discrepancy 
between the methods makes values for the two methods 
not interchangeable in the follow up of monoclonal 
gammopathy [4, 6–8]. Improving the quantitative perfor­
mance of the FLC assay might improve the clinical man­
agement of plasma cell disorders.
To establish to what extent the discrepancy between 
Freelite® and N Latex FLC is due to the different reactivity 
against oligomers, we decided to perform FLC analysis on 
plasma protein separated in fractions of different mole­
cular weight obtained from the sample of a patient with 
multiple myeloma and elevated plasma λ FLC (Freelite 
1360 mg/dL; N Latex 724 mg/dL).
The plasma sample was subjected to molecular size 
exclusion chromatography using a Superdex­75 10/300 
column (volume: 24 mL; GE Healthcare, Little Chalfonts, 
UK). Fractions (0.5 mL) containing proteins in the range 
from 100 to 5 kDa, thus including FLC monomers and oli­
gomers, but not intact immunoglobulins, were then col­
lected and individually analyzed by a BNII nephelometer 
(Siemens) with the two FLC reagents.
Strikingly different elution profiles of FLC were seen 
(Figure  1A). The elution profile obtained by N Latex 
FLC revealed only one peak at 12.5 kDa, while Freelite® 
revealed a minute peak ( < 1% of the total reactivity) at 
12.5  kDa, and almost all reactivity was concentrated in 
a peak at a molecular weight of approximately 50 kDa, 
apparently corresponding to FLC dimers. Both reagents 
failed to reveal a peak corresponding to the molecular 
weight expected for FLC monomers (25 kDa).
To check if the peaks corresponded to different forms 
of FLC, the same fractions were analyzed by nephelo­
metry by an anti­λ light chains antiserum not restricted 
for FLC, provided by Siemens (N Antiserum to Human 
Ig/L­Chain, Type λ). The profile obtained was similar to 
the one obtained with the Freelite® (Figure 1A). To exclude 
a possible cross­ reactivity, the same  fractions were also 
analyzed by N Latex β2­microglobulin (Siemens) reagent, 
which showed that β2­microglobulin elutes later than the 
peak identified by N Latex FLC reagent (Figure 1A).
When a sample from the same patient, drawn 2 
months later, and showing similarly discordant values 
of λ FLC (Freelite® 2400 mg/dL; N Latex 315 mg/dL), was 
treated with dithiothreitol (DTT) prior to chromatography 
both N Latex and Freelite® revealed only a wide peak at 
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25 kDa, while not only the peak at 50 kDa but also the one 
at 12.5 kDa had disappeared (Figure 1B).
Western blot analysis of the fractions collected was 
then performed by using an anti­λ light chains antiserum 
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Figure 1: Gel-filtration chromatography elution profiles.
The amount of λ FLC or whole λ light chains or β2-microglobulin meas-
ured in each fraction under non-reducing conditions are shown in (A); 
elution profiles after dithiothreitol (DTT) treatment of the samples and 
the amount of FLC measured in each fraction is plotted in (B).
as a primary antibody (Figure 2A–D). In completely non­
reducing conditions (i.e. sample not treated with DTT, nor 
β­mercaptoethanol in the sample buffer), a high molecular 
weight band was seen, more abundant in fractions 23–24, 
corresponding to the 50 kDa peak detected by the Freelite® 
reagent, while another distinct band at a lower molecular 
weight appeared in later fractions, mostly in fraction 28, 
corresponding to the 12.5  kDa peak detected by N Latex 
(Figure 2A). The cross reactivity with β2­microglobulin was 
clearly also excluded by immunoblot (Figure 2D and E).
When the same fractions were loaded under reduc­
ing conditions, with β­mercaptoethanol included in the 
loading buffer, the same band of FLC was seen in all frac­
tions, at a molecular weight of approximately 25 kDa, thus 
corresponding to the one expected for monomeric FLC. In 
these conditions, not only the band corresponding to FLC 
dimers, but also the FLC band at lower molecular weight 
(in Western blot appearing at 20 kDa, probably following 
the denaturing action of SDS) disappeared (Figure 2B).
These findings allowed us to exclude that the FLC 
immunoreactive protein detected by N Latex FLC at 
12.5 kDa corresponds to an FLC fragment, while it is likely 
that intra­molecular protein disulfide bonds decrease the 
apparent molecular weight of the FLC monomer, which 
shows its expected value only upon reduction by DTT or 
β­mercaptoethanol.
Indeed, when we subjected it to non­reducing Western 
blot analysis the gel filtration fractions obtained from 
samples treated with DTT before chromatography, a major 
band of FLC was found in fraction 26, corresponding to an 
apparent molecular weight of 25 kDa and no immunoreac­
tive FLC protein was found in the fractions corresponding 
to 12.5 kDa and 50 kDa (Figure 2C).
In conclusion, the present findings suggest that the 
different estimation of FLC oligomers is not the only bias 
of FLC assays: gel filtration chromatography allowed us 
to distinguish in the same sample two different molecu­
lar forms of λ FLC with different molecular weights. These 
forms, apparently dimer and monomer of the same mono­
clonal protein, besides displaying different molecular 
weight, display different antigenic properties, resulting in 
the monomeric form being selectively recognized by the 
N­Latex assay and the dimeric form by the Freelite® assay.
Thiol reduction experiments and Western blot analy­
sis allowed us to conclude that the formation of protein 
disulfides between FLC monomers may hide epitopes 
critical for the N Latex FLC, while the Freelite® assay may 
fail to recognize FLC monomers with oxidized protein 
thiols.
No conclusions can be drawn concerning the nature 
or the position of the protein disulfides involved, and 
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further study is needed to establish to which extent the 
redox chemistry of protein thiols influences FLC assay in 
the clinical setting, and if this is a general feature of FLC 
or affects only specific samples. Hopefully, such future 
studies will allow a better understanding of the relation­
ship between structure and pathogenetic properties of the 
monoclonal FLC.
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Figure 2: Western blot analysis of fractions obtained by gel-filtration chromatography.
Fractions obtained by gel-filtration chromatography were loaded onto polyacrylamide gel in the absence (A) or presence (B) of 
β-mercaptoethanol. Fractions obtained by gel-filtration chromatography performed in the presence of dithiothretitol were loaded 
without β-mercaptoethanol (C). Nitrocellulose membranes (A–C) were incubated with the Siemens anti-λ antiserum not restricted for 
FLC as a primary antibody; Western blot analysis performed to exclude the possible cross reactivity of the N Latex λ FLC reactive with 
β2-microglobulin: in (D) the anti-λ light chains antiserum reveals FLC monomers and dimers but not purified β2-microglobulin; in (E) the anti-
β2-microglobulin antiserum (anti-β2 antiserum HRP labeled; The Binding Site) reveals only its specific antigen (B2M).
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